Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's Disease.

Parkinson’s disease digital health technology meaningfulness qualitative

Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2023
Historique:
medline: 20 6 2023
pubmed: 22 5 2023
entrez: 22 5 2023
Statut: ppublish

Résumé

Patient perspectives on meaningful symptoms and impacts in early Parkinson's disease (PD) are lacking and are urgently needed to clarify priority areas for monitoring, management, and new therapies. To examine experiences of people with early-stage PD, systematically describe meaningful symptoms and impacts, and determine which are most bothersome or important. Forty adults with early PD who participated in a study evaluating smartwatch and smartphone digital measures (WATCH-PD study) completed online interviews with symptom mapping to hierarchically delineate symptoms and impacts of disease from "Most bothersome" to "Not present," and to identify which of these were viewed as most important and why. Individual symptom maps were coded for types, frequencies, and bothersomeness of symptoms and their impacts, with thematic analysis of narratives to explore perceptions. The three most bothersome and important symptoms were tremor, fine motor difficulties, and slow movements. Symptoms had the greatest impact on sleep, job functioning, exercise, communication, relationships, and self-concept- commonly expressed as a sense of being limited by PD. Thematically, most bothersome symptoms were those that were personally limiting with broadest negative impact on well-being and activities. However, symptoms could be important to patients even when not present or limiting (e.g., speech, cognition). Meaningful symptoms of early PD can include symptoms that are present or anticipated future symptoms that are important to the individual. Systematic assessment of meaningful symptoms should aim to assess the extent to which symptoms are personally important, present, bothersome, and limiting.

Sections du résumé

BACKGROUND
Patient perspectives on meaningful symptoms and impacts in early Parkinson's disease (PD) are lacking and are urgently needed to clarify priority areas for monitoring, management, and new therapies.
OBJECTIVE
To examine experiences of people with early-stage PD, systematically describe meaningful symptoms and impacts, and determine which are most bothersome or important.
METHODS
Forty adults with early PD who participated in a study evaluating smartwatch and smartphone digital measures (WATCH-PD study) completed online interviews with symptom mapping to hierarchically delineate symptoms and impacts of disease from "Most bothersome" to "Not present," and to identify which of these were viewed as most important and why. Individual symptom maps were coded for types, frequencies, and bothersomeness of symptoms and their impacts, with thematic analysis of narratives to explore perceptions.
RESULTS
The three most bothersome and important symptoms were tremor, fine motor difficulties, and slow movements. Symptoms had the greatest impact on sleep, job functioning, exercise, communication, relationships, and self-concept- commonly expressed as a sense of being limited by PD. Thematically, most bothersome symptoms were those that were personally limiting with broadest negative impact on well-being and activities. However, symptoms could be important to patients even when not present or limiting (e.g., speech, cognition).
CONCLUSION
Meaningful symptoms of early PD can include symptoms that are present or anticipated future symptoms that are important to the individual. Systematic assessment of meaningful symptoms should aim to assess the extent to which symptoms are personally important, present, bothersome, and limiting.

Identifiants

pubmed: 37212071
pii: JPD225068
doi: 10.3233/JPD-225068
pmc: PMC10357209
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S. Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

619-632

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Parkinsonism Relat Disord. 2019 Oct;67:56-59
pubmed: 31621608
Qual Health Res. 2003 Jul;13(6):871-83
pubmed: 12891720
Value Health. 2018 Jun;21(6):631-639
pubmed: 29909867
Neurol Clin Pract. 2020 Feb;10(1):65-72
pubmed: 32190422
J Parkinsons Dis. 2021;11(4):1957-1964
pubmed: 34250951
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Mov Disord. 2019 May;34(5):657-663
pubmed: 30901495
NPJ Parkinsons Dis. 2023 Apr 17;9(1):64
pubmed: 37069193
Front Neurosci. 2017 Oct 06;11:555
pubmed: 29056899
Res Nurs Health. 2014 Feb;37(1):3-8
pubmed: 24307343
J Parkinsons Dis. 2022;12(1):137-151
pubmed: 34657850
J Parkinsons Dis. 2021;11(2):715-724
pubmed: 33459664
J Parkinsons Dis. 2023;13(4):589-607
pubmed: 37212073
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
ANS Adv Nurs Sci. 1995 Mar;17(3):1-13
pubmed: 7778887
Int J Nurs Stud. 2016 Jun;58:90-96
pubmed: 26897540
Neurol Ther. 2022 Sep;11(3):1319-1340
pubmed: 35778541
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Parkinsonism Relat Disord. 2013 Nov;19(11):1027-32
pubmed: 23916654
Mov Disord. 2018 Aug;33(8):1248-1266
pubmed: 29570866
Mov Disord. 2014 Feb;29(2):195-202
pubmed: 24123307

Auteurs

Jennifer R Mammen (JR)

University of Rhode Island, College of Nursing, Providence, RI, USA.

Rebecca M Speck (RM)

Critical Path Institute, Tucson, AZ, USA.

Glenn T Stebbins (GT)

Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.

Martijn L T M Müller (MLTM)

Critical Path Institute, Tucson, AZ, USA.

Phillip T Yang (PT)

Center for Health + Technology, University of Rochester, Rochester, NY, USA.

Michelle Campbell (M)

Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.

Josh Cosman (J)

Abbvie Inc., North Chicago, IL, USA.

Tien Dam (T)

Biogen, Cambridge, MA, USA.

Johan Hellsten (J)

H. Lundbeck A/S, Valby, Denmark.

Stella Jensen-Roberts (S)

Center for Health + Technology, University of Rochester, Rochester, NY, USA.

Melissa Kostrzebski (M)

Center for Health + Technology, University of Rochester, Rochester, NY, USA.
Department of Neurology, University of Rochester, Rochester, NY, USA.

Tanya Simuni (T)

Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Kimberly Ward Barowicz (KW)

Critical Path Institute, Tucson, AZ, USA.

Jesse M Cedarbaum (JM)

Coeruleus Clinical Sciences LLC, Woodbridge, CT, USA.
Yale Medical School, New Haven, CT, USA.

E Ray Dorsey (ER)

Center for Health + Technology, University of Rochester, Rochester, NY, USA.
Department of Neurology, University of Rochester, Rochester, NY, USA.

Diane Stephenson (D)

Critical Path Institute, Tucson, AZ, USA.

Jamie L Adams (JL)

Center for Health + Technology, University of Rochester, Rochester, NY, USA.
Department of Neurology, University of Rochester, Rochester, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH